{"id":"bg9418-interferon-beta-1a","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"30-50","effect":"Injection site reactions"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"10-15","effect":"Lymphopenia"},{"rate":"5-10","effect":"Depression or mood changes"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a binds to interferon-beta receptors on cell surfaces, triggering intracellular signaling cascades that enhance antiviral and immunomodulatory effects. This leads to increased expression of interferon-stimulated genes, reduced pro-inflammatory cytokine production, and restoration of immune tolerance. In multiple sclerosis, these mechanisms help reduce relapse rates and slow disease progression.","oneSentence":"BG9418 is interferon beta-1a, which activates interferon signaling pathways to modulate immune responses and reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:09.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing-remitting or relapsing forms)"}]},"trialDetails":[{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT05936229","phase":"PHASE1, PHASE2","title":"Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-04-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02076841","phase":"","title":"Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-07","conditions":"Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS), Multiple Sclerosis","enrollment":40},{"nctId":"NCT01272128","phase":"","title":"Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-12","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT00616434","phase":"PHASE2","title":"A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-05","conditions":"Active Ulcerative Colitis","enrollment":123},{"nctId":"NCT00168714","phase":"","title":"Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)","status":"COMPLETED","sponsor":"Biogen","startDate":"2004-02","conditions":"Prenatal Exposure Delayed Effects, Multiple Sclerosis, Pregnancy","enrollment":329},{"nctId":"NCT00828204","phase":"PHASE3","title":"Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-01","conditions":"Multiple Sclerosis","enrollment":95},{"nctId":"NCT00784836","phase":"PHASE3","title":"Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients","status":"TERMINATED","sponsor":"Biogen","startDate":"2008-10","conditions":"Multiple Sclerosis","enrollment":3},{"nctId":"NCT01313364","phase":"PHASE1","title":"A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle","status":"TERMINATED","sponsor":"Biogen","startDate":"2011-03","conditions":"Healthy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avonex","Avonex®"],"phase":"phase_3","status":"active","brandName":"BG9418 (interferon beta-1a)","genericName":"BG9418 (interferon beta-1a)","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BG9418 (interferon beta-1a) is a medication used to treat relapsing-remitting multiple sclerosis. It is also being studied in the context of prenatal exposure and pregnancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}